OncoMatch/Clinical Trials/NCT06756152
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Is NCT06756152 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 for biphenotypic acute leukemia.
Treatment: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 — GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Lab requirements
Kidney function
clearance of endogenous creatinine ≥ 70 ml / min
Liver function
total bilirubin, ALT, AST, ALP ≤ 2 norms
Cardiac function
left ventricular ejection fraction ≥ 40% according to ultrasound of the heart
Heart function: left ventricular ejection fraction <40% according to ultrasound of the heart; Kidney function: clearance of endogenous creatinine < 70 ml / min; Liver function: total bilirubin, ALT, AST, ALP > 2 norms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify